About Incyte Corporation
A mid-cap biopharma anchored by Jakafi for blood cancer disorders. No dividend, low beta (~0.4). Core revenue is stable but pipeline events add occasional volatility. Thin premiums — suits conservative sellers wanting biotech without the fireworks.
Biotechnology